BioPorto expects fast US penetration
Denmark’s BioPorto still aims to break even in 2016 and US approval of a new product and subsequent launch will play a huge role in fulfilling that ambition. The CEO expects the development to be markedly different in Europe.
BY STEFAN SINGH KAILAY
I have four bullet points for you. We are on track. We have secured growth. We have reduced our losses. We are on the verge on becoming a profitable company.”
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
BioPorto denies rumors in the market
For abonnenter
BioPorto CFO switches to Novo-owned company
For abonnenter
BioPorto CEO: Not optimal looking back
For abonnenter
